Skip to main content
Premium Trial:

Request an Annual Quote

VelaDx Receives CE-IVD for NGS-Based HIV Genotyping Assay

NEW YORK (GenomeWeb) – Vela Diagnostics announced today that its next-generation sequencing-based Sentosa SQ HIV genotyping assay is now CE-IVD marked for in vitro diagnostic usage.The company plans to use the assay to detect HIV-1 Group M genomic mutations in protease, reverse transcriptase, and integrase regions from plasma in patients with HIV.

The Sentosa NGS workflow that the company's assay runs on enables automated RNA extraction, library construction, template preparation, sequencing, data analysis, and generation of both a pathology and a quality control report. Vela's workflow also allows clear sample traceability, as well as laboratory information system integration and connectivity.   

The automated workflow processes clinical samples with as low as 1,000 copies per ml of HIV viral load, Vela said, adding the assay detects as low as 5 percent variant frequency at 4,000 copies per ml viral load. It has demonstrated 98.5 percent clinical sensitivity in all three target regions and 99.8 percent detection correctness, with 100 percent reproducibility.

Earlier this summer, Vela received regulatory approval for its Sentosa assay in Australia.

The Scan

Less Than Half

An effort to reproduce key findings from high-profile preclinical cancer studies finds less than half could be replicated, according to the Scientist.

Still Some SARS-CoV-2 Sequencing Holes

The Wall Street Journal reports that viral genomic surveillance has improved in the US, though says there are still gaps.

Avoiding Passing Them On

People with known disease-linked genetic variants are turning to in vitro fertilization so as to not pass those variants to their children, the Washington Post says.

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

In PNAS this week: long, cell-free DNA of maternal and fetal origins identified in maternal plasma, and more.